Tarceva 150mg (Erlotinib Tablet) 150mg

Tarceva 150mg (Erlotinib) tablets are prescribed for certain cancer treatments. This oral medication supports targeted therapy with convenient once-daily dosing. Suitable for patients managing specific conditions under medical supervision. Always follow healthcare provider instructions when using this product.

Strength

150mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

F.Hoffman La Roche Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tarceva 150mg (Erlotinib) is a targeted therapy tablet used to treat specific types of cancer, including non-small cell lung cancer and pancreatic cancer. It works by blocking signals that promote cancer cell growth. Patients often use this medication when other treatments are not suitable. Always consult a healthcare professional to determine if this treatment is appropriate.

Side Effects

Tarceva 150mg (Erlotinib) tablets may cause mild to moderate side effects such as nausea, rash, or fatigue. Some users report digestive discomfort or changes in appetite. Skin reactions like dryness or itching are common. These effects vary by individual and should be monitored by a healthcare provider.

Precautions & Warnings

Keep Tarceva 150mg (Erlotinib) tablets at room temperature and away from moisture. Store in the original packaging to protect from light. Handle with care and avoid crushing or splitting unless advised by a doctor. Keep out of reach of children and pets. Report any unusual symptoms to a healthcare professional promptly.

Avoid Interactions

Tarceva 150mg (Erlotinib) may interact with certain medications, including strong CYP3A4 inhibitors or inducers. Avoid grapefruit products while taking this medication. Discuss all current prescriptions, supplements, and herbal remedies with your doctor. Alcohol use should be limited and monitored during treatment.

References

Frequently Asked Questions

Tarceva 150mg (Erlotinib) is used to treat specific types of cancer, including non-small cell lung cancer and pancreatic cancer.

Store Tarceva 150mg at room temperature in a dry place, away from light and moisture.

Tarceva 150mg can be taken with or without food, but consistency in timing is recommended.

Common side effects include rash, nausea, fatigue, and digestive discomfort.

Yes, it may interact with CYP3A4 inhibitors, inducers, and grapefruit products.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.